Literature DB >> 21170084

BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma.

J H Hsu1, E R Lawlor.   

Abstract

The polycomb group family protein BMI-1 is overexpressed by and functions as an oncogene in many different human cancers. We have previously shown that BMI-1 promotes the tumorigenicity of Ewing sarcoma family tumors (ESFTs) and that this is mediated independently of CDKN2A repression. In this study, we have discovered that high levels of BMI-1 confer resistance to contact inhibition in ESFT cells. Using stable retroviral transduction, we evaluated the consequences of BMI-1 knockdown on the growth of CDKN2A wild-type and mutant ESFT cells in subconfluent and confluent conditions. Although knockdown of BMI-1 had no effect on proliferation in low-density cultures, at high cell densities it resulted in cell cycle arrest and death. The normal cell contact inhibition response is mediated, in large part, by the recently described Hippo pathway which functions to inhibit cell proliferation and promote cell death by inactivating the Yes-Associated Protein (YAP). Significantly, we found that YAP levels, activity and expression did not diminish in confluent ESFT cells that expressed high levels of BMI-1. In contrast, YAP expression and nuclear localization were reduced in confluent BMI-1 knockdown cells suggesting that silencing of BMI-1 restored contact inhibition by restoring normal activation of the Hippo-YAP growth-suppressor pathway. Importantly, knockdown of YAP in ESFT cells resulted in profound inhibition of cell proliferation and anchorage-independent colony formation suggesting that stabilization and continued expression of YAP is critical for ESFT growth and tumorigenicity. Together, these studies reveal a previously unrecognized link between BMI-1, contact inhibition and the Hippo-YAP pathway and suggest that resistance to contact inhibition in BMI-1 overexpressing cancer cells may be in part a result of Hippo inhibition and aberrant stabilization of YAP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170084      PMCID: PMC3276065          DOI: 10.1038/onc.2010.571

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  The FERM-domain protein Expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie.

Authors:  Caroline Badouel; Laura Gardano; Nancy Amin; Ankush Garg; Robyn Rosenfeld; Thierry Le Bihan; Helen McNeill
Journal:  Dev Cell       Date:  2009-03       Impact factor: 12.270

Review 2.  Polycomb group proteins: navigators of lineage pathways led astray in cancer.

Authors:  Adrian P Bracken; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

3.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Authors:  Katherine Striedinger; Scott R VandenBerg; Gilson S Baia; Michael W McDermott; David H Gutmann; Anita Lal
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

4.  The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity.

Authors:  Wassim Chatoo; Mohamed Abdouh; Jocelyn David; Marie-Pier Champagne; José Ferreira; Francis Rodier; Gilbert Bernier
Journal:  J Neurosci       Date:  2009-01-14       Impact factor: 6.167

5.  YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation.

Authors:  Africa Fernandez-L; Paul A Northcott; James Dalton; Charles Fraga; David Ellison; Stephane Angers; Michael D Taylor; Anna Marie Kenney
Journal:  Genes Dev       Date:  2009-12-01       Impact factor: 11.361

6.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.

Authors:  Günther H S Richter; Stephanie Plehm; Annette Fasan; Sabine Rössler; Rebekka Unland; Idriss M Bennani-Baiti; Marc Hotfilder; Diana Löwel; Irene von Luettichau; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Heinrich Kovar; Martin S Staege; Carsten Müller-Tidow; Stefan Burdach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

7.  BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression.

Authors:  Dorothea Douglas; Jessie Hao-Ru Hsu; Long Hung; Aaron Cooper; Diana Abdueva; John van Doorninck; Grace Peng; Hiro Shimada; Timothy J Triche; Elizabeth R Lawlor
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

8.  Bmi1 regulates mitochondrial function and the DNA damage response pathway.

Authors:  Jie Liu; Liu Cao; Jichun Chen; Shiwei Song; In Hye Lee; Celia Quijano; Hongjun Liu; Keyvan Keyvanfar; Haoqian Chen; Long-Yue Cao; Bong-Hyun Ahn; Neil G Kumar; Ilsa I Rovira; Xiao-Ling Xu; Maarten van Lohuizen; Noboru Motoyama; Chu-Xia Deng; Toren Finkel
Journal:  Nature       Date:  2009-04-29       Impact factor: 49.962

9.  Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways.

Authors:  Sonal Datta; Mark J Hoenerhoff; Prashant Bommi; Rachana Sainger; Wei-Jian Guo; Manjari Dimri; Hamid Band; Vimla Band; Jeffrey E Green; Goberdhan P Dimri
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

10.  Is Ewing's sarcoma a stem cell tumor?

Authors:  Paul S Meltzer
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

View more
  15 in total

Review 1.  YAP and the Hippo pathway in pediatric cancer.

Authors:  Atif A Ahmed; Abdalla D Mohamed; Melissa Gener; Weijie Li; Eugenio Taboada
Journal:  Mol Cell Oncol       Date:  2017-02-25

2.  Expression of Yes-associated protein (YAP) in breast phyllodes tumor.

Authors:  Sang Kyum Kim; Woo Hee Jung; Ja Seung Koo
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation.

Authors:  Katherine E Ryland; Allegra G Hawkins; Daniel J Weisenberger; Vasu Punj; Scott C Borinstein; Peter W Laird; Jeffrey R Martens; Elizabeth R Lawlor
Journal:  Mol Cancer Res       Date:  2015-11-16       Impact factor: 5.852

Review 4.  Epigenetic changes in pediatric solid tumors: promising new targets.

Authors:  Elizabeth R Lawlor; Carol J Thiele
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

5.  Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.

Authors:  Kelli L Goss; David J Gordon
Journal:  Oncotarget       Date:  2016-09-27

6.  Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.

Authors:  Corinne Bouvier; Nicolas Macagno; Quy Nguyen; Anderson Loundou; Carine Jiguet-Jiglaire; Jean-Claude Gentet; Jean-Luc Jouve; Alexandre Rochwerger; Jean-Camille Mattei; Daniel Bouvard; Sébastien Salas
Journal:  Oncotarget       Date:  2016-10-04

7.  Akt and Hippo Pathways in Ewing's Sarcoma Tumors and Their Prognostic Significance.

Authors:  Atif A Ahmed; Malak Abedalthagafi; Ahmed E Anwar; Marilyn M Bui
Journal:  J Cancer       Date:  2015-08-22       Impact factor: 4.207

Review 8.  A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.

Authors:  Michael D Deel; Jenny J Li; Lisa E S Crose; Corinne M Linardic
Journal:  Front Oncol       Date:  2015-09-02       Impact factor: 6.244

9.  Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.

Authors:  Katherine K Slemmons; Lisa E S Crose; Erin Rudzinski; Rex C Bentley; Corinne M Linardic
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.